ECEmma Castro

Emma Castro

*This is an algorithmically generated author record based on publicly available information.

Emma Castro has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • J. L. Bueno

    Centro de Transfusión de Cruz Roja Española en Madrid, Madrid, Spain

    2 shared publications
  • Javier Carrión

    ICPVet Research Group, Department of Animal Health, Faculty of Veterinary Medicine, Complutense University of Madrid, 28040 Madrid, Spain

    2 shared publications
  • Manuel Fresno

    Centro de Biologia Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain

    2 shared publications
  • Núria Gironès

    Centro de Biologia Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain

    2 shared publications
  • David A. Leiby

    From the American Red Cross Holland Laboratories, Rockville, Maryland; the American Red Cross Scientific Support Office, Gaithersburg, Maryland; Canadian Blood Services, Toronto, Ontario, Canada; and Centro de Transfusiónde Cruz Roja Espanola, Madrid, Spain

    1 shared publication
  • Fernando José García López

    National Epidemiology Centre, Carlos III Health Institute, 28029 Madrid, Spain

    1 shared publication

Latest Publications

  • Trypanosoma cruzi infection in North America and Spain: evidence in support of transfusion transmission (CME)

    by Richard J. Benjamin, Susan L. Stramer, David A. Leiby, Roger Y. Dodd, Margaret Fearon, Emma Castro

    BACKGROUND: The United States, Canada, and Spain perform selective testing of blood donors for Trypanosoma cruzi infection (Chagas disease) to prevent transfusion transmission. The donor, product, and patient characteristics associated with transfusion‐transmitted infections are reviewed and the infectivity of components from donors with serologic evidence of infection is estimated.STUDY DESIGN AND METHODS: A systematic review of transfusion‐transmitted T. cruzi cases and recipient tracing undertaken in North America and Spain is described. Cases were assessed for the imputability of the evidence for transfusion transmission.RESULTS: T. cruzi infection in 20 transfusion recipients was linked to 18 serologically confirmed donors between 1987 and 2011, including 11 identified only by recipient tracing. Cases were geographically widely distributed and were not associated with incident or autochthonous infections. Index clinical cases were described only in immunocompromised patients. All definite transmissions (n = 11) implicated apheresis or whole blood–derived platelets (PLTs), including leukoreduced and irradiated products. There is no evidence of transmission by red blood cells (RBCs) or frozen products, while transmission by whole blood transfusion remains a possibility. Recipient tracing reveals low component infectivity from serologically confirmed, infected donors of 1.7% (95% confidence interval [CI], 0.7%‐3.5%) overall: 13.3% (95% CI, 5.6%‐25.7%) for PLTs, 0.0% (95% CI, 0.0%‐1.5%) for RBCs, and 0.0% (95% CI, 0%‐3.7%) for plasma and cryoprecipitate.CONCLUSIONS: T. cruzi is transmitted by PLT components from some donors with serologic evidence of infection. Evidence of transmission before the implementation of widespread testing in the countries studied is sparse, and selective testing of only PLT and fresh whole blood donations should be considered.


  • Chagas’ disease: lessons from routine donation testing

    by E. Castro

    American Trypanosomiasis, or Chagas' disease, is a parasitic infection caused by the protozoan Trypanosoma cruzi. It is endemic in a large area of the American continent, extending from Mexico to Argentina. Imported Chagas' disease is now appearing as a new threat to non-endemic countries, mostly because of a steady increase of foreign residents from Latin America. Chagas' disease becomes chronic in the vast majority of infected individuals. This finding gives rise to problems for blood transfusion services. In non-endemic countries, transfusion is the most likely infection route. Strategies to reduce transmission by transfusion include blood donor selection and deferral, blood donation testing, leukoreduction, filters and pathogen inactivation systems. Policies in endemic and non-endemic areas are quite different: in endemic countries, universal screening of blood donations for T. cruzi antibody detection is mandatory. However, in non-endemic countries, there are two different approaches: one is the deferral of people at risk of Chagas' disease and the second approach is to accept the blood donation if specific laboratory assay results are negative. This second approach is being introduced in countries where there is a substantial Latin American population, such as United States, Spain and France. The assays used for the detection of T. cruzi are mostly immunologic, made with T. cruzi antigen homogenates or with recombinant antigens. Complementary assays, such as indirect immunofluorescence (IIF) or immunoblot, can help ascertain antibody specificity.


  • The efficacy of photochemical treatment with amotosalen HCl and ultraviolet A (INTERCEPT) for inactivation ofTrypanosoma cruziin pooled buffy‐coat platelets

    by Emma Castro, Nuria Gironés, José Luis Bueno, Javier Carrión, Lily Lin, Manuel Fresno

    BACKGROUND:This study evaluated the efficacy of photochemical treatment (PCT) with amotosalen and ultraviolet A (UVA) light to inactivateTrypanosoma cruziin contaminated platelet (PLT) components.STUDY DESIGN AND METHODS:Fifteen pools of buffy‐coat PLTs (BC‐PLTs) were inoculated with approximately 5 × 103to 5 × 105per mL of viableT. cruziof the G, Tulahuen (T), or Y strains. Samples from BC‐PLTs were assayed for infectivity before and after PCT with 150 µmol per L amotosalen and 3 J per cm2UVA light. Infectivity was determined with three different methods: 1) in vitro culture to detect viable epimastigotes, 2) [3H]thymidine incorporation in culture, and 3) in vivo inoculation into interferon‐γ receptor (IFN‐γR)‐deficient mice.RESULTS:The in vitro assay yielded viable parasite titers of 3.9 × 105, 2.8 × 104, and 5.6 × 103per mL (corresponding to 5.6, 4.4, and 3.8 logs/mL) for the Y, T, and G strains, respectively. PCT was able to inactivate all three strains ofT. cruzito below the limit of detection (10 parasites/mL) in the sensitive in vivo assay. Because 10‐mL samples, each concentrated into a 1‐mL sample for inoculation, were tested in the in vivo assay, log reductions achieved were greater than 5.6, greater than 4.4, and greater than 3.8 for the Y, T, and G strains ofT. cruzi, respectively.CONCLUSIONS:The pathogen reduction system with amotosalen HCl and UVA demonstrated robust efficacy for inactivation of high doses of three different strains ofT. cruziand offers the potential to make the PLT supply safer.


  • The efficacy of photochemical treatment with methylene blue and light for the reduction ofTrypanosoma cruziin infected plasma

    by N. Gironés, J. L. Bueno, J. Carrión, M. Fresno, E. Castro

    Background and Objectives Chagas disease is a transfusion‐transmitted infection. This study evaluates the efficacy of a methylene blue (MB) and light system for reducing the viability ofTrypanosoma cruziin plasma.Materials and Methods Trypanosoma cruzistrains were spiked in plasma pools. Treatment arms included combined filtration, MB, light and freezing. Post‐treatment parasite viability was assayed throughin vitrocultures andin vivoinoculation in inducible nitric oxide synthase‐ and interferon‐γ‐receptor‐deficient mice.Results The filtration, MB and light combined treatment showed a log reduction of > 3·4 inin vitrocultures, and log reductions that ranged from > 4·9 to > 5·8 in deficient mice inoculated with differentT. cruzistrains.Conclusion The treatment of plasma units with the MB and light system reduces theT. cruziburden and could be useful in preventing transfusion‐transmitted Chagas disease.


  • A randomized crossover trial comparing three plateletpheresis machines

    by José Luis Bueno, Fernando García, Emma Castro, Luisa Barea, Rocío González

    The aim of the study was to compare three different apheresis machines with the same donors regarding the processing time required to obtain a 3.5 x 10(11) platelet (PLT) dose and acceptance by donors. A randomized crossover trial was performed to evaluate the differences between the Amicus Crescendo (Baxter Biotech Corp.), the MCS Plus (Haemonetics Corp.), and the Trima Accel (Gambro BCT). Donations from 51 donors were compared for time adjusted to obtain a standard 3.5 x 10(11) PLT dose (TSD3.5), efficiency, adverse reactions, yield, leukodepletion, machine accuracy, and donor preferences. Processing times were measured by chronometer. The same vein access was used during all three processes in each donor. In the statistical analysis, to take into account the nonindependence of several measurements from the same donor, generalized estimating equations were used with an autoregressive correlation matrix. The Accel produced a TSD3.5 (mean +/- SEM) of 47.9 +/- 1.0 min; the Amicus, 60.3 +/- 1.0 min; and the MCS Plus, 66.7 +/- 1.0 (p < 0.0001). The Amicus presented the greatest efficiency (87.5%; p < 0.0028). The MCS Plus demonstrated the highest capacity for leukodepletion (p < 0.0002) despite one process presenting more than 1 x 10(6) white blood cells per unit. The MCS Plus also measured the processing time with the greatest accuracy. No severe adverse effects were observed. The donors preferred the Accel (61%) followed by the Amicus (35%) and the MCS Plus (4%; p < 0.0001) and the processing speed was the most highly valued measure (55%). The Accel is the fastest and, because of this advantage, the machine preferred by donors. The Amicus was the most efficient and the MCS Plus was the only one not to underestimate the processing time.


  • Feasibility of implementing an automated culture system for bacteria screening in platelets in the blood bank routine

    by E Castro, J. L. Bueno, L. Barea, R. González

    Summary. Bacterial contamination of blood components is the principal infectious complication linked to transfusion. The aim of the study was to evaluate the applicability of an automated culture system for platelets. 10 141 platelet concentrates were cultured individually and in pools of five on storage days 1 and 7 using Bact/Alert system aerobic bottles. A modified collection bag was used for improved sampling. Five‐millilitre samples were cultured at 37 °C for 7 days. Only those samples where the same bacteria were identified in reculture were considered true positives (TP). Homogeneity of proportions was tested by Fisher's exact test. The rate of TP was 30 per 100 000 (95% CI, 6·1–86·4) sampling on day 1; 33 per 100 000 (95% CI, 7–96) on day 7; and 40 per 100 000 (95% CI, 1·28–122·4) if the screening was based on taking both samples (day 1 and 7). Only one TP was detected in the pool testing. The time for detection among TPs on day 1 ranged between 30 and 134 h. The system is not considered practical for use as a routine screening method, as the time for detection is too long. Pool testing is insensitive. Faster screening methods or pathogen‐inactivation systems are needed.